Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Yamamoto, Kazuhiro ^a   Uda, Atsushi ^a   Mukai, Akira ^a   Yamashita, Kazuhiko ^a   Kume, Manabu ^a   Makimoto, Hiroo ^a   Bito, Toshinori ^b   Nishigori, Chikako ^b   Hirano, Takeshi ^a,b   Hirai, Midori ^a,b  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Everolimus; Hand foot skin reaction; Keratinocyte; Skin rush; Skin toxicity; STAT3

Indexed keywords

EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SERINE; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CELL GROWTH; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CYTOMETRY; CYTOSTASIS; CYTOTOXICITY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; HEP G2 CELLS; HUMANS; KERATINOCYTES; SIGNAL TRANSDUCTION; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84886198504     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-83     Document Type: Article

References (51)

1. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Yang CH, Chuang CK, Hsieh JJ, Chang JW, Expert Opin Drug Saf 2010 9 459 470 10.1517/14740331003596349 20113155
2. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M, J Clin Oncol 2010 28 1351 1357 10.1200/JCO.2008.21.7828 20142600
3. The hand-foot-syndrome associated with medical tumor therapy- classification and management. Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, Gutzmer R, J Dtsch Dermatol Ges 2010 8 652 661 20482685
4. mTOR inhibitor-associated dermatologic and mucosal problems. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E, Clin Transplant 2010 24 149 156 10.1111/j.1399-0012.2010.01232.x 20236129
5. Chemotherapeutic agents and the skin: an update. Heidary N, Naik H, Burgin S, J Am Acad Dermatol 2008 58 545 570 10.1016/j.jaad.2008.01.001 18342708 (Pubitemid 351375051)
6. Role of the mTOR complex 1 pathway in the in vivo maintenance of the intestinal mucosa by oral intake of amino acids. Nakamura A, Hara K, Yamamoto K, Yasuda H, Moriyama H, Hirai M, Nagata M, Yokono K, Geriatr Gerontol Int 2012 12 131 139 10.1111/j.1447-0594.2011.00729.x 21794051
7. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Kahan BD, Lancet 2000 356 194 202 10.1016/S0140-6736(00)02480-6 10963197 (Pubitemid 30446974)
8. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE, Sirolimus European Psoriasis Study Group, Br J Dermatol 2001 2001 145 438 445 (Pubitemid 32953701)
9. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Mahé E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, Mamzer-Bruneel MF, de Prost Y, Kreis H, Bodemer C, Transplantation 2005 79 476 482 10.1097/01.TP.0000151630.25127.3A 15729175 (Pubitemid 40280181)
10. STATs and gene regulation. Darnell JE Jr, Science 1997 277 1630 1635 10.1126/science.277.5332.1630 9287210 (Pubitemid 27446219)
11. Stats: transcriptional control and biological impact. Levy DE, Darnell JE Jr, Nat Rev Mol Cell Biol 2002 3 651 662 12209125 (Pubitemid 34987786)
12. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Jarnicki A, Putoczki T, Ernst M, Cell Div 2010 5 14 10.1186/1747-1028-5-14 20478049
13. Functional roles of STAT family proteins: lessons from knockout mice. Akira S, Stem Cells 1999 17 138 146 10.1002/stem.170138 10342556 (Pubitemid 29226664)
14. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Aoki Y, Feldman GM, Tosato G, Blood 2003 101 1535 1542 10.1182/blood-2002-07-2130 12393476 (Pubitemid 36182531)
15. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Sen N, Che X, Rajamani J, Zerboni L, Sung P, Ptacek J, Arvin AM, Proc Natl Acad Sci U S A 2012 109 600 605 10.1073/pnas.1114232109 22190485
16. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Schust J, Sperl B, Hollis A, Mayer TU, Berg T, Chem Biol 2006 13 1235 1242 10.1016/j.chembiol.2006.09.018 17114005 (Pubitemid 44750735)
17. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Song H, Wang R, Wang S, Lin J, Proc Natl Acad Sci U S A 2005 102 4700 4705 10.1073/pnas.0409894102 15781862 (Pubitemid 40471517)
18. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP, Mol Cancer Ther 2008 7 2308 2318 10.1158/1535-7163.MCT- 08-0279 18723478
19. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE, J Cell Biol 1988 106 761 771 10.1083/jcb.106.3.761 2450098 (Pubitemid 18089976)
20. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N, Yokoyama T, Cancer Lett 2009 278 88 96 10.1016/j.canlet.2008.12.033 19201079
21. Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells. Takara K, Matsubara M, Yamamoto K, Minegaki T, Takegami S, Takahashi M, Yokoyama T, Okumura K, Mol Med Report 2012 5 603 609
22. Effects of Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport. Takara K, Yamamoto K, Matsubara M, Minegaki T, Takahashi M, Yokoyama T, Okumura K, PLoS One 2012 7 30697 10.1371/journal.pone.0030697 22355323
23. Stat3 as an Oncogene. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr, Cell 1999 98 295 303 10.1016/S0092- 8674(00)81959-5 10458605 (Pubitemid 29380565)
24. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Wen Z, Darnell JE Jr, Nucleic Acids Res 1997 25 2062 2067 10.1093/nar/25.11.2062 9153303 (Pubitemid 27303439)
25. EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El-Deiry WS, Nakagawa H, Am J Physiol Gastrointest Liver Physiol 2006 290 404 416 10.1152/ajpgi.00344.2005
26. EGFR activation confers protections against UV-induced apoptosis in cultured mouse skin dendritic cells. Cao C, Lu S, Jiang Q, Wang WJ, Song X, Kivlin R, Wallin B, Bagdasarian A, Tamakloe T, Chu WM, Marshall J, Kouttab N, Xu A, Wan Y, Cell Signal 2008 20 1830 1838 10.1016/j.cellsig.2008.06.010 18644433
27. Zinc inhibits H(2)O(2)-induced MC3T3-E1 cells apoptosis via MAPK and PI3K/AKT pathways. Liang D, Yang M, Guo B, Cao J, Yang L, Guo X, Li Y, Gao Z, Biol Trace Elem Res 2012 148 420 429 10.1007/s12011-012-9387-8 22434380
28. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW, J Am Acad Dermatol 2007 56 317 326 10.1016/j.jaad.2006.09.005 17141360 (Pubitemid 46091817)
29. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. McLellan B, Kerr H, Dermatol Ther 2012 24 396 400
30. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N, Toriyabe T, Shinozaki Y, Ooka Y, Mikata R, Chiba T, Okabe S, Imazeki F, Yoshikawa M, Yokosuka O, Hepatol Int 2011 5 850 856 10.1007/s12072-010-9249-4 21484134
31. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Quadros MR, Peruzzi F, Kari C, Rodeck U, Cancer Res 2004 64 3934 3939 10.1158/0008-5472.CAN-04-0214 15173005 (Pubitemid 38697307)
32. The STAT3 oncogene as a predictive marker of drug resistance. Barré B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O, Trends Mol Med 2007 13 4 11 10.1016/j.molmed.2006.11.001 17118707 (Pubitemid 46027724)
33. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B, Ann N Y Acad Sci 2009 1171 59 76 10.1111/j.1749-6632.2009.04911.x 19723038
34. Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Lufei C, Koh TH, Uchida T, Cao X, Oncogene 2007 26 7656 7664 10.1038/sj.onc.1210567 17563747 (Pubitemid 350224213)
35. Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. Martinet W, Verheye S, De Meyer I, Timmermans JP, Schrijvers DM, Van Brussel I, Bult H, De Meyer GR, Arterioscler Thromb Vasc Biol 2012 32 1228 1235 10.1161/ATVBAHA.112.245381 22345170
36. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Aksamitiene E, Kiyatkin A, Kholodenko BN, Biochem Soc Trans 2012 40 139 146 10.1042/BST20110609 22260680
37. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML, Lacout C, Guilhot F, Vainchenker W, Turhan AG, Br J Haematol 2006 134 171 179 10.1111/j.1365-2141. 2006.06161.x 16846476 (Pubitemid 43893908)
38. Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. Lo RK, Cheung H, Wong YH, J Biol Chem 2003 278 52154 52165 10.1074/jbc.M307299200 14551213 (Pubitemid 38035802)
39. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R, Mol Cell Biol 1999 19 7519 7528 10523640 (Pubitemid 29493415)
40. Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway. Yang F, Zhang W, Li D, Zhan Q, J Biol Chem 2013 288 6552 6560 10.1074/jbc.M112.418335 23329839
41. Serine phosphorylation and negative regulation of Stat3 by JNK. Lim CP, Cao X, J Biol Chem 1999 274 31055 31061 10.1074/jbc.274.43.31055 10521505 (Pubitemid 29503949)
42. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. Lu PH, Kuo TC, Chang KC, Chang CH, Chu CY, Br J Dermatol 2011 164 38 46 10.1111/j.1365-2133. 2010.10038.x 20846305
43. Stat3 activation is required for cell proliferation and tumorigenesis but not for cell viability in cutaneous squamous cell carcinoma cell lines. Sumita N, Bito T, Nakajima K, Nishigori C, Exp Dermatol 2006 15 291 299 10.1111/j.0906-6705.2006.00407.x 16512876 (Pubitemid 43349070)
44. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, Baraldo M, Franceschi L, Furlanut M, Viale P, Ann Pharmacother 2008 42 1711 1716 10.1345/aph.1L330 18812562
45. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Crowe A, Lemaire M, Pharm Res 1998 15 1666 1672 10.1023/A: 1011940108365 9833985 (Pubitemid 28524574)
46. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H, Cancer Res 2009 69 2506 2513 10.1158/0008-5472.CAN-08-4323 19244102
47. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O, J Clin Oncol 2007 25 2785 2791 10.1200/JCO.2006.09.8897 17602083 (Pubitemid 47123187)
48. Analysis of dermatologic events in patients with cancer treated with lapatinib. Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, Gomez HL, Salazar VM, Byrne JA, Koch KM, Blackwell KL, Breast Cancer Res Treat 2009 114 485 493 10.1007/s10549-008-0020-7 18600445
49. Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Sano S, Chan KS, Kira M, Kataoka K, Takagi S, Tarutani M, Itami S, Kiguchi K, Yokoi M, Sugasawa K, Mori T, Hanaoka F, Takeda J, DiGiovanni J, Cancer Res 2005 65 5720 5729 10.1158/0008-5472.CAN-04-4359 15994947 (Pubitemid 40911175)
50. Mitogen-activated protein kinase activation in UV-induced signal transduction. Bode AM, Dong Z, Sci STKE 2003 2003 E2 12554854
51. AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytes. Cao C, Lu S, Kivlin R, Wallin B, Card E, Bagdasarian A, Tamakloe T, Chu WM, Guan KL, Wan Y, J Biol Chem 2008 283 28897 28908 10.1074/jbc.M804144200 18715874